Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window
Intravenous rhTNK-tPA Versus Placebo Before Endovascular Thrombectomy For Stroke Patient With Large Vessel Occlusion In The Extended Time Window: the BRIDGE-TNK EXTEND Randomized, Placebo-controlled, Double-blind Trial
Sponsor: China Shijiazhuang Pharmaceutical Company RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTD
Listed as NCT06987305, this PHASE3 trial focuses on Stroke, Acute Ischemic and remains actively recruiting participants. Sponsored by China Shijiazhuang Pharmaceutical Company RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTD, it has been updated 2 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
2 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2025 — Jan 2026 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- China Shijiazhuang Pharmaceutical Company RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTD
- The First Affiliated Hospital of Nanchang University
- Xinqiao Hospital of Chongqing
For direct contact, visit the study record on ClinicalTrials.gov .